217 related articles for article (PubMed ID: 19363468)
1. CRAdRGDflt-IL24 virotherapy in combination with chemotherapy of experimental glioma.
Kaliberova LN; Krendelchtchikova V; Harmon DK; Stockard CR; Petersen AS; Markert JM; Gillespie GY; Grizzle WE; Buchsbaum DJ; Kaliberov SA
Cancer Gene Ther; 2009 Oct; 16(10):794-805. PubMed ID: 19363468
[TBL] [Abstract][Full Text] [Related]
2. YB-1 dependent virotherapy in combination with temozolomide as a multimodal therapy approach to eradicate malignant glioma.
Holzmüller R; Mantwill K; Haczek C; Rognoni E; Anton M; Kasajima A; Weichert W; Treue D; Lage H; Schuster T; Schlegel J; Gänsbacher B; Holm PS
Int J Cancer; 2011 Sep; 129(5):1265-76. PubMed ID: 21710499
[TBL] [Abstract][Full Text] [Related]
3. Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivo.
Ulasov IV; Sonabend AM; Nandi S; Khramtsov A; Han Y; Lesniak MS
Br J Cancer; 2009 Apr; 100(7):1154-64. PubMed ID: 19277041
[TBL] [Abstract][Full Text] [Related]
4. A dual-regulated oncolytic adenovirus expressing interleukin-24 sensitizes melanoma cells to temozolomide via the induction of apoptosis.
Jiang G; Jiang AJ; Cheng Q; Tian H; Li LT; Zheng JN
Tumour Biol; 2013 Apr; 34(2):1263-71. PubMed ID: 23430584
[TBL] [Abstract][Full Text] [Related]
5. The timing of neural stem cell-based virotherapy is critical for optimal therapeutic efficacy when applied with radiation and chemotherapy for the treatment of glioblastoma.
Tobias AL; Thaci B; Auffinger B; Rincón E; Balyasnikova IV; Kim CK; Han Y; Zhang L; Aboody KS; Ahmed AU; Lesniak MS
Stem Cells Transl Med; 2013 Sep; 2(9):655-66. PubMed ID: 23926209
[TBL] [Abstract][Full Text] [Related]
6. Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma.
Kim SM; Woo JS; Jeong CH; Ryu CH; Jang JD; Jeun SS
Stem Cells Transl Med; 2014 Feb; 3(2):172-82. PubMed ID: 24436439
[TBL] [Abstract][Full Text] [Related]
7. Combination of the oncolytic adenovirus ICOVIR-5 with chemotherapy provides enhanced anti-glioma effect in vivo.
Alonso MM; Gomez-Manzano C; Jiang H; Bekele NB; Piao Y; Yung WK; Alemany R; Fueyo J
Cancer Gene Ther; 2007 Aug; 14(8):756-61. PubMed ID: 17557108
[TBL] [Abstract][Full Text] [Related]
8. Humanized chondroitinase ABC sensitizes glioblastoma cells to temozolomide.
Jaime-Ramirez AC; Dmitrieva N; Yoo JY; Banasavadi-Siddegowda Y; Zhang J; Relation T; Bolyard C; Wojton J; Kaur B
J Gene Med; 2017 Mar; 19(3):. PubMed ID: 28087981
[TBL] [Abstract][Full Text] [Related]
9. Enhanced antitumor efficacy of a novel oncolytic adenovirus combined with temozolomide in the treatment of melanoma in vivo.
Jiang G; Sun C; Li RH; Wei ZP; Zheng JN; Liu YQ
J Cancer Res Clin Oncol; 2015 Jan; 141(1):75-85. PubMed ID: 25103017
[TBL] [Abstract][Full Text] [Related]
10. Transcriptional targeting of adenovirally delivered tumor necrosis factor alpha by temozolomide in experimental glioblastoma.
Yamini B; Yu X; Gillespie GY; Kufe DW; Weichselbaum RR
Cancer Res; 2004 Sep; 64(18):6381-4. PubMed ID: 15374943
[TBL] [Abstract][Full Text] [Related]
11. Systemic administration of mesenchymal stem cells loaded with a novel oncolytic adenovirus carrying IL-24/endostatin enhances glioma therapy.
Zhang J; Chen H; Chen C; Liu H; He Y; Zhao J; Yang P; Mao Q; Xia H
Cancer Lett; 2021 Jul; 509():26-38. PubMed ID: 33819529
[TBL] [Abstract][Full Text] [Related]
12. Local delivery of slow-releasing temozolomide microspheres inhibits intracranial xenograft glioma growth.
Dong J; Zhou G; Tang D; Chen Y; Cui B; Dai X; Zhang J; Lan Q; Huang Q
J Cancer Res Clin Oncol; 2012 Dec; 138(12):2079-84. PubMed ID: 22825126
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic herpes simplex virus mutants exhibit enhanced replication in glioma cells evading temozolomide chemotherapy through deoxyribonucleic acid repair.
Aghi M; Rabkin S; Martuza RL
Clin Neurosurg; 2006; 53():65-76. PubMed ID: 17380741
[No Abstract] [Full Text] [Related]
14. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of glioma radiotherapy and chemotherapy response with targeted antibody therapy against death receptor 5.
Fiveash JB; Gillespie GY; Oliver PG; Zhou T; Belenky ML; Buchsbaum DJ
Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):507-16. PubMed ID: 18474311
[TBL] [Abstract][Full Text] [Related]
16. An armed, YB-1-dependent oncolytic adenovirus as a candidate for a combinatorial anti-glioma approach of virotherapy, suicide gene therapy and chemotherapeutic treatment.
Kostova Y; Mantwill K; Holm PS; Anton M
Cancer Gene Ther; 2015 Jan; 22(1):30-43. PubMed ID: 25501992
[TBL] [Abstract][Full Text] [Related]
17. Combined therapy of oncolytic adenovirus and temozolomide enhances lung cancer virotherapy in vitro and in vivo.
Gomez-Gutierrez JG; Nitz J; Sharma R; Wechman SL; Riedinger E; Martinez-Jaramillo E; Sam Zhou H; McMasters KM
Virology; 2016 Jan; 487():249-59. PubMed ID: 26561948
[TBL] [Abstract][Full Text] [Related]
18. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
[TBL] [Abstract][Full Text] [Related]
19. The integrin inhibitor cilengitide enhances the anti-glioma efficacy of vasculostatin-expressing oncolytic virus.
Fujii K; Kurozumi K; Ichikawa T; Onishi M; Shimazu Y; Ishida J; Chiocca EA; Kaur B; Date I
Cancer Gene Ther; 2013 Aug; 20(8):437-44. PubMed ID: 23827879
[TBL] [Abstract][Full Text] [Related]
20. Aplysin enhances temozolomide sensitivity in glioma cells by increasing miR-181 level.
Gong A; Ge N; Yao W; Lu L; Liang H
Cancer Chemother Pharmacol; 2014 Sep; 74(3):531-8. PubMed ID: 25047724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
